PROCESS AND MOLECULAR BIOMARKER

Abstract

A process and molecular biomarker for platelets stored in blood banks provides for efficient verification of which platelet concentrate bags are in good condition for transfusion by measuring, by real-time polymerase chain reaction, expression levels of hsa-miR-127 and hsa-miR-320a microRNAs as the first process and biomarker predictor of platelet's cell aging during storage and the consequent presence of storage lesions as a quality test of these bags.

Description

The process and molecular biomarker refer to a process of detection and quantification of the expression of hsa-miR-127 and hsa-miR-320a microRNAs in platelets, specifically in platelets stored in a blood bank, as a means of ascertaining the aging cell process during the storage period and consequent presence of storage lesions, disabling the platelet concentrate bags to the donation.

The bags of platelet concentrates stored in blood banks at the present time are discarded after five days because there are no rapid quality tests that can detect the presence of storage lesions in these bags and the consequent cell aging and quality of the transfusion bags.

In the absence of a quality test, the use of bags stored for periods longer than five days would be a risk to patient's health. However, discarding all bags that reach this deadline may compromise blood bank platelet stores.

The molecular biomarker efficiently verifies which platelets concentrate bags are in good condition for transfusion, increasing the reliability in the quality of the platelet concentrate bags and reducing waste. This process will quantify by real-time polymerase chain reaction the concentration of the hsa-miR-127 and hsa-miR-320a microRNAs and through the mir127/320a relation will determine the quality of the bags, thus ensuring greater patient safety.

The process and molecular biomarker for platelets stored in blood banks consists of isolating the hsa-miR-127 and hsa-miR-320a microRNAs from a small sample of each bag selected for transfusion, followed by quantification of the expression of these microRNAs. The quantitative relationship between these two microRNAs determines the quality of the stored platelets. Bags whose expression of hsa-miR-127 is greater than or equal to the expression of hsa-miR-320a will be suitable for transfusion. However, bags where the expression of hsa-miR-127 is less than the expression of hsa-miR-320a should be discarded because they are not safe for transfusion.

Claims

1: A process and molecular biomarker for platelets, specifically for platelets stored in a blood bank, which comprises detecting and quantifying an expression of hsa-miR-127 and hsa-miR-320a microRNAs in platelets for detecting cell aging during storage and consequent presence of storage lesions, disabling the bag of platelet concentrate to the donation.

2: The process and molecular biomarker according to claim 1, wherein the process is based on a ratio of hsa-miR-127 and hsa-miR-320a microRNAs expression which undergo quantitative change over a course of the storage time, detected by real-time polymerase chain reaction.

3: The process and molecular biomarker according to claim 1, wherein when hsa-miR-127 expression is greater than or equal to the expression of hsa-miR-320a it is a sign the platelets have not undergone aging during storage, and there are no lesions of storage in the platelets, and the bag is determined to be suitable for donation.

4: The process and molecular biomarker according to claim 1, wherein when the hsa-miR-127 expression is lower than hsa-miR-320a expression it is a sign the platelets have undergone aging during storage and the bag is determined to be not suitable for donation.

5: The process and molecular biomarker according to claim 1, which comprises the first quality assay of platelet concentrate bags, stored in blood bank for transfusion, with a fast and reliable results.

6: The process and molecular biomarker according to claim 2, wherein when hsa-miR-127 expression is greater than or equal to the expression of hsa-miR-320a it is a sign the platelets have not undergone aging during storage, and there are no lesions of storage in the platelets, and the bag is determined to be suitable for donation.

7: The process and molecular biomarker according to claim 2, wherein when the hsa-miR-127 expression is lower than hsa-miR-320a expression it is a sign the platelets have undergone aging during storage and the bag is determined to be not suitable for donation.

8: The process and molecular biomarker according to claim 2, which comprises the first quality assay of platelet concentrate bags, stored in blood bank for transfusion, with a fast and reliable results.

9: The process and molecular biomarker according to claim 3, wherein when the hsa-miR-127 expression is lower than hsa-miR-320a expression it is a sign the platelets have undergone aging during storage and the bag is determined to be not suitable for donation.

10: The process and molecular biomarker according to claim 3, which comprises the first quality assay of platelet concentrate bags, stored in blood bank for transfusion, with a fast and reliable results.

11: The process and molecular biomarker according to claim 4, which comprises the first quality assay of platelet concentrate bags, stored in blood bank for transfusion, with a fast and reliable results.